Charles River Laboratories Intl. Inc vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $48.35 (market cap $561.25M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 25.4× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 50 Days on average.
| CRL | QCLN | |
|---|---|---|
Market Cap | $14.23B | $561.25M |
Volume | 1,176,885 | 323,550 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $68.47 |
52-Week Low | $149.93 | $41.10 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
QCLN trades at $48.35, down 2.2% today, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's performance is heavily influenced by U.S. clean energy policy and geopolitical developments, with recent news highlighting global renewable energy acceleration amid tensions. Support and resistance levels cluster around $50-$52, indicating a key price zone for near-term direction.
The outlook for QCLN hinges on political support for clean energy and rising electricity demand, offering growth potential but facing volatility from policy shifts. Risks include regulatory uncertainty and competitive pressures, while analyst sentiment remains watchful amid evolving market dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →